1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

FDA Urges Full Participation In Quality Metrics Program

 
• By Joanne S. Eglovitch

Despite the voluntary nature of US FDA’s program, an agency official urges full participation. Without data from such participation, FDA will not be able to predict drug shortages and industry will not see the benefits of reduced inspections and streamlined change control.

Pharmaceutical companies should participate in FDA’s quality metrics program and submit metrics data once an electronic portal goes live Jan. 1, 2018, Ashley Boam, acting director for the FDA’s Office of Policy for Pharmaceutical Quality, said Feb. 22 at the Parenteral Drug Association’s meeting on quality metrics and quality culture in Bethesda Md.

Without participation, the program will not succeed, as FDA will not have enough information to predict drug shortages and the...

Welcome to Pink Sheet

Create an account to read this article

Already a subscriber?

More from Manufacturing

EU’s Draft GMP Guideline Signals Major Cultural Shift In Pharma Quality Compliance

 
• By Vibha Sharma

While the EU's draft good manufacturing practice guideline on pharmaceutical quality systems reflects modern quality management principles, it also presents significant operational and resource challenges for drug companies.

EU GMP Changes Target Supply Chain Risks And Product Shortages

 
• By Vibha Sharma

The European Commission’s proposed update of its good manufacturing practice guideline on pharmaceutical quality system calls for smarter risk management to safeguard drug quality and supply.

Ultra-Rare Cancers Partnership Launches With Two Pilot Indications, Seeks Industry Help

 
• By Sue Sutter

A molecular target and platform technology for each indication will be selected at a November public meeting, while sustainable manufacturing issues remain ongoing.

EU Critical Medicines Act: Parliament Clarifies ‘Significant Proportion’ Rule

 
• By Eliza Slawther

The European Parliament has suggested clear rules on the proportion of medicinal product manufacturing that must take place in the EU, EEA, or Switzerland for drugmakers to be favored under the Critical Medicines Act, which aims to drive investment in Europe.

More from Compliance

US FDA DTC Ad Crackdown Could Force Shift In Spending, Regulatory Focus

 
• By Jessica Merrill

Ad spending changes in response to the FDA's new DTC policy could force the agency to shift the focus of its regulatory resources.

E-Pharmacies In India: Mind The Data Privacy Gap, Regulatory Deficit

 
• By Anju Ghangurde

Legal and other experts discuss the need to plug data privacy and regulatory gaps and address prescription shortcuts at e-pharmacies. Collaborative models with brick and mortar chemists were also proposed.

US FDA Reveals DTC Enforcement Approach In Letter For AstraZeneca’s FluMist Ad

 
• By Derrick Gingery

FDA Commissioner Martin Makary also wrote in a JAMA article that the agency is not banning pharmaceutical advertising, but said industry has exploited weak enforcement.